P. Patel

发表

UK Multicenter Prospective Evaluation of the Leibovich Score in Localized Renal Cell Carcinoma: Performance has Altered Over Time

S. Bhattarai, D. Hrouda, N. Vasudev, 2019, Urology.

Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative

J. Blay, M. Sydes, A. Benson, 2015, European journal of cancer.

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.

Tae Min Kim, Ray Page, R. Motzer, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Escherichia coli Lipopolysaccharide and Type 1 Piliated Activation of Bladder Epithelial Cells by CD14- and Toll-Like Receptor-Dependent

S. Hultgren, P. Patel, D. Schilling, 2014 .

Stromal fibroblasts support dendritic cells to maintain IL-23/Th17 responses after exposure to ionizing radiation

P. Patel, A. Saalbach, A. Jackson, 2016, Journal of leukocyte biology.

Identification of proteins regulated by interferon‐α in resistant and sensitive malignant melanoma cell lines

P. Selby, P. Patel, R. Banks, 2004, Proteomics.

Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma

I. Ellis, P. Patel, J. Newton-Bishop, 2011, Modern Pathology.

Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.

J. Ajani, C. Reed, K. Bhalla, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer.

D. Khayat, P. Vasey, P. Selby, 2008, European journal of cancer.

New anticancer immunotherapies.

P. Patel, Qunwei Wang, H. Franks, 2012, Anticancer research.

Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer

D. Hrouda, N. Vasudev, P. Selby, 2020, BMJ Open.

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.

D. Schadendorf, M. Gore, A. Eggermont, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exploring the Experiences of Cancer Patients With Chemotherapy-Induced Ototoxicity: Qualitative Study Using Online Health Care Forums

D. Hoare, D. Baguley, P. Patel, 2019, JMIR cancer.

Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials.

J. Coebergh, A. Eggermont, T. Nijsten, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results

P. Ascierto, S. Aamdal, A. Eggermont, 2008 .

Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.

D. Schadendorf, R. Dummer, A. Testori, 2012, European journal of cancer.

Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.

D. Schadendorf, R. Dummer, M. Gore, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The genetic vulnerability to cisplatin ototoxicity: a systematic review

B. Canlon, E. Tserga, D. Baguley, 2019, Scientific Reports.

Cytokine modulation of cell growth and role in tumour therapy.

P. Patel, M. Collins, 1992, European journal of cancer.

Surface polymer imprinted optical fibre sensor for dose detection of dabrafenib.

S. Morgan, P. Patel, C. Alexander, 2020, The Analyst.

Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia

Andrew K. Brown, Sarah L. Field, P. Emery, 2004, Arthritis research & therapy.

Generation of interleukin-2-secreting melanoma cell populations from resected metastatic tumors.

M. Gore, J. Thomas, P. Patel, 1994, Human gene therapy.

Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial

R. Plummer, H. Pandha, P. Lorigan, 2018, Oncoimmunology.

Comparison of the potential therapeutic effects of interleukin 2 or interleukin 4 secretion by a single tumour.

K. Maclennan, S. Russell, M. Collins, 1993, British Journal of Cancer.

Ulceration of primary melanoma and responsiveness to adjuvant interferon therapy: Analysis of the adjuvant trials EORTC18952 and EORTC18991 in 2,644 patients.

A. Eggermont, A. Testori, P. Patel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumors.

G. Mufti, F. Farzaneh, P. Patel, 1997, Human gene therapy.

The effect of combined expression of interleukin 2 and interleukin 4 on the tumorigenicity and treatment of B16F10 melanoma.

S. Humphreys, G. Mufti, F. Farzaneh, 1996, British Journal of Cancer.

Comparison ofthepotential therapeutic effects ofinterleukin 2or interleukin 4secretion byasingle tumour

K. Maclennan, S. Russell, M. Collins, 1993 .

The Ataxia Telangiectasia Mutated Kinase Pathway Regulates IL-23 Expression by Human Dendritic Cells

C. Seedhouse, S. Madhusudan, P. Patel, 2013, The Journal of Immunology.

Human Dendritic Cells Pathway Regulates IL-23 Expression by The Ataxia Telangiectasia Mutated Kinase

Madhusudan, C. Seedhouse, P. Patel, 2013 .

Human Cells Pathway Regulates IL-23 Expression by The Ataxia Telangiectasia Mutated Kinase

Madhusudan, C. Seedhouse, P. Patel, 2013 .

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

P. Dziewulski, M. Gore, M. Highley, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Novel approach for interleukin‐23 up‐regulation in human dendritic cells and the impact on T helper type 17 generation

P. Patel, J. Crooks, J. Porte, 2011, Immunology.

Interleukin 12: a new clinical player in cytokine therapy.

P. Selby, P. Patel, R. Banks, 1995, British Journal of Cancer.

A randomised phase II study of interferon alpha alone or in combination with thalidomide in metastatic renal cancer

A. Harris, D. Altman, K. Christodoulos, 2004 .

Sarcoma cells engineered to secrete IFN-gamma or IL-2 acquire sensitization to immune cell killing via different mechanisms.

M. Collins, S. Eccles, P. Patel, 1997, Cytokine.

Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952.

A. Eggermont, V. Cocquyt, P. Patel, 2011, European journal of cancer.

Prognostic value of autoantibodies (auto-AB) in melanoma patients (pts) in the EORTC 18952 trial of adjuvant interferon (IFN) compared to observation (obs)

A. Eggermont, C. Punt, P. Patel, 2007 .

The response of human dendritic cells to recombinant adenovirus, recombinant Mycobacterium bovis Bacillus Calmette Guerin and biolistic methods of antigen delivery: different induction of contact-dependant and soluble signals.

P. Selby, P. Patel, S. Smith, 2001, Immunology letters.

Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer.

T. Powles, F. Thistlethwaite, P. Patel, 2020 .

Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.

S. Aamdal, A. Eggermont, C. Punt, 2009, Journal of the National Cancer Institute.

Melanoma Group achievements

D. Schadendorf, M. Mihm, A. Eggermont, 2012 .

Abstract 9035: An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells in vivo, in fully resected melanoma patients

R. Plummer, P. Lorigan, P. Patel, 2015 .

Clinical and Immunobiological Effects of Subcutaneous Recombinant Human Interleukin 12 in Patients with Metastatic Renal Cancer

M. Wadhwa, P. Dilger, R. Thorpe, 2002 .

A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma

J. Larkin, M. Gore, P. Patel, 2006, British Journal of Cancer.

Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.

A. Eggermont, A. Testori, C. Punt, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Simultaneous Estimation of Lamivudine and Stavudine by using RP-HPLC and Method Development as per ICH Guidelines

P. Patel, P. Hariprasad, Shri B. M. Shah, 2012 .

Cytokine‐modified Mycobacterium smegmatis as a novel anticancer immunotherapy

P. Selby, M. Murphy, P. Patel, 2004, International journal of cancer.

Vestibulotoxicity Associated With Platinum-Based Chemotherapy in Survivors of Cancer: A Scoping Review

D. Hall, D. Baguley, P. Patel, 2018, Front. Oncol..

Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer.

P. Patel, A. Jackson, S. Nicholson, 2010, Immunotherapy.

Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.

D. Schadendorf, R. Dummer, A. Testori, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel function for the p38-MK2 signaling pathway in circulating CD1c+ (BDCA-1+) myeloid dendritic cells from healthy donors and advanced cancer patients; inhibition of p38 enhances IL-12 whilst suppressing IL-10

M. Collins, P. Patel, A. Jackson, 2013, International journal of cancer.

Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials.

A. Hauschild, D. Schadendorf, K. Flaherty, 2014, The Lancet. Oncology.

IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines

Ian O Ellis, I. Ellis, E. Paish, 2008, Breast Cancer Research.

Impaired circulating myeloid CD1c+ dendritic cell function in human glioblastoma is restored by p38 inhibition – implications for the next generation of DC vaccines

P. Patel, A. Jackson, M. Schmitz, 2019, Oncoimmunology.

Proteomic analysis of melanoma‐derived exosomes by two‐dimensional polyacrylamide gel electrophoresis and mass spectrometry

P. Selby, P. Patel, R. Banks, 2004, Proteomics.

Cancer survivors treated with platinum-based chemotherapy affected by ototoxicity and the impact on quality of life: a narrative synthesis systematic review

D. Baguley, P. Patel, Stephanie E Pearson, 2019, International journal of audiology.

Biology of advanced uveal melanoma and next steps for clinical therapeutics

Erwin G. Van Meir, A. Bowcock, K. Flaherty, 2014, Pigment cell & melanoma research.

Ran GTPase is an independent prognostic marker in malignant melanoma which promotes tumour cell migration and invasion

M. Ilyas, P. Rudland, M. Aleskandarany, 2020, Journal of Clinical Pathology.

Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma

P. Patel, A. Jackson, Julia Moreno-Vicente, 2020, Cells.

The genetic vulnerability to cisplatin ototoxicity: a systematic review

B. Canlon, E. Tserga, D. Baguley, 2019, Scientific Reports.

Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)

T. Powles, F. Thistlethwaite, P. Patel, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort

D. Schadendorf, D. Bishop, G. Jönsson, 2015, Oncotarget.

Immuno-silent polymer capsules encapsulating nanoparticles for bioimaging applications.

P. Patel, A. Jackson, S. Sivakumar, 2017, Journal of materials chemistry. B.

Intrinsic chemotherapy resistance to the tubulin‐binding antimitotic agents in renal cell carcinoma

P. Selby, R. Ferguson, P. Patel, 2005, International journal of cancer.

Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma.

M. Gore, R. A’Hern, P. Selby, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).

D. Schadendorf, R. Dummer, A. Eggermont, 2011, European journal of cancer.

Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial

P. Royston, M. Parmar, M. Gore, 2010 .

Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.

M. Gore, A. Eggermont, C. Punt, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumour‐mediated disruption of dendritic cell function: Inhibiting the MEK1/2‐p44/42 axis restores IL‐12 production and Th1‐generation

P. Patel, A. Jackson, Xingwu Zhu, 2008, International journal of cancer.

Role of mitogen-activated protein kinase and PI 3 K pathways in the regulation of IL-12-family cytokines in dendritic cells and the generation of TH-responses

P. Patel, A. Jackson, Xingwu Zhu, 2010 .

Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: Final results of study EORTC 18961.

P. Ascierto, S. Aamdal, A. Eggermont, 2010 .

Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.

A. Eggermont, C. Punt, P. Patel, 2006, European journal of cancer.

Resistance to the Tubulin-Binding Agents in Renal Cell Carcinoma: No Mutations in the Class I β-Tubulin Gene but Changes in Tubulin Isotype Protein Expression

Rosamonde E Banks, C. Taylor, P. Selby, 2005, Clinical Cancer Research.

Prognostic Factors in Renal Cell Carcinoma: Association of Preoperative Sodium Concentration with Survival

N. Vasudev, P. Selby, Janet E Brown, 2008, Clinical Cancer Research.

EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-α2b (PEG-IFN) versus observation in resected stage III melanoma: Long-term results at 7.6-years follow-up.

D. Schadendorf, R. Dummer, M. Gore, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The prognostic significance of non‐sentinel lymph node metastasis in cutaneous and acral melanoma patients—A multicenter retrospective study

Jilong Yang, P. Patel, Wangjun Yan, 2020, Cancer communications.

Immunotherapy for intracranial metastatic melanoma

A. Bryant, P. Patel, Christina Peters, 2021 .

5LB Prognostic value of autoantibodies in melanoma stage III patients in the EORTC 18991 phase III randomized trial comparing adjuvant pegylated interferon α2b vs observation

A. Eggermont, A. Testori, C. Punt, 2007 .

Serum S-100B protein is a strong independent prognostic marker for distant-metastasis free survival (DMFS) in stage III melanoma patients: An evaluation of the EORTC randomized trial 18952 comparing IFNα versus observation

A. Eggermont, G. Ghanem, P. Patel, 2007 .

Low calpain-9 is associated with adverse disease-specific survival following endocrine therapy in breast cancer

I. Ellis, A. Green, E. Rakha, 2014, BMC Cancer.

Clinical Grade OK432-activated Dendritic Cells: In Vitro Characterization and Tracking During Intralymphatic Delivery

A. Dietz, A. Melcher, C. Twelves, 2009, Journal of immunotherapy.

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma

A. Eggermont, B. Dréno, F. Brasseur, 2005, International journal of cancer.

EORTC Melanoma Group achievements

D. Schadendorf, M. Mihm, A. Eggermont, 2012 .

Dacarbazine, cisplatin and IFN-alpha with or without IL-2 in advanced melanoma (EORTC trial 18951)

M. Gore, A. Eggermont, C. Punt, 2000 .

A comparative study of adhesion of melanoma and breast cancer cells to blood and lymphatic endothelium.

P. Patel, Stewart G. Martin, S. Storr, 2012, Lymphatic research and biology.

2-[(1-Methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation

A. Westwell, P. Patel, K. Huber, 2008, Molecular Cancer Therapeutics.

Reply to F. Janku et al

A. Bottomley, A. Eggermont, A. Testori, 2010 .

1067 Analysis of the EORTC Melanoma Group 18952 randomized trial on 2 intermediate dose schedules of IFN-alpha2b compared with observation in 1388 patients with high risk melanoma stages IIB-III

A. Eggermont, A. Testori, C. Punt, 2003 .

Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.

P. Ascierto, S. Aamdal, L. Bastholt, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

323 POSTER In vitro evaluation of potential thioredoxin inhibitors in breast cancer and endothelial cells

L. Zhang, A. Westwell, T. Bradshaw, 2006 .

Inherited variation in the PARP1 gene and survival from melanoma

Dirk Schadendorf, Susana Puig, Johan Hansson, 2014, International journal of cancer.

Human dendritic cells genetically engineered to express a melanoma polyepitope DNA vaccine induce multiple cytotoxic T-cell responses.

P. Selby, P. Patel, J. Porte, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Renal carcinoma cell lines inhibit natural killer activity via the CD94 receptor molecule

P. Selby, P. Patel, R. Banks, 2001, Cancer Immunology, Immunotherapy.

Production and Characterization of Monoclonal Antibodies to Human Interleukin-12

M. Wadhwa, C. Bird, R. Thorpe, 1997 .

Prospects for tumour therapy using gene transfer.

S. Eccles, P. Patel, M. Collins, 1992, Bone marrow transplantation.

Cytoplasmic expression of p27(kip1) is associated with a favourable prognosis in colorectal cancer patients.

I. Ellis, J. Scholefield, P. Patel, 2006, World journal of gastroenterology.

Non‐invasive time‐course imaging of apoptotic cells by confocal Raman micro‐spectroscopy

Ioan Notingher, Alina Zoladek, P. Patel, 2011 .

Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).

R. Motzer, K. Pittman, C. Barrios, 2015 .

The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line

I. Kerr, P. Selby, P. Patel, 2003, Melanoma research.

Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy

G. Ball, A. Jadhav, A. Simeonov, 2014, Oncotarget.

SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)

R. Plummer, S. Leyvraz, P. Lorigan, 2019, Annals of Oncology.

Synthetic lethal targeting of DNA double‐strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors

C. Laughton, P. Fischer, C. Seedhouse, 2012, International journal of cancer.

Gene manipulation in the induction of anti-tumour immunity

P. Patel, C. Sousa, D. O'Donnell, 1999, Gene Therapy.

The p53 positive Bcl‐2 negative phenotype is an independent marker of prognosis in breast cancer

I. Ellis, E. Rakha, P. Patel, 2007, International journal of cancer.

Low calpain-9 is associated with adverse disease-specific survival following endocrine therapy in breast cancer

I. Ellis, A. Green, E. Rakha, 2014, BMC Cancer.

1099 A phase II study of ABR-214936 (anatumomab mafenatox) tumour targeted superantigen (TTS) therapy in patients with advanced renal cell carcinoma (RCC)

P. Stern, C. Garner, P. Patel, 2003 .

Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines

L. Dekker, C. Laughton, P. Fischer, 2011, British Journal of Cancer.

Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC).

R. Motzer, K. Pittman, C. Barrios, 2013 .

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.

V. Goh, T. Powles, M. Highley, 2023, The Lancet. Oncology.

Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma

L. Egevad, A. Brazma, G. Bourque, 2023, Clinical Cancer Research.

Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer.

T. Powles, F. Thistlethwaite, P. Patel, 2021 .

Meta-Analysis in Metastatic Uveal Melanoma to Determine Progression-Free and Overall Survival Benchmarks: an International Rare Cancers Initiative (IRCI) Ocular Melanoma study.

P. Huppert, S. Patel, S. Leyvraz, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: a 10-year real-world retrospective cohort study

S. Welsh, G. Aithal, P. Patel, 2023, JHEP Reports.

Phorbol ester enhances integrin alpha IIb beta 3-dependent adhesion of human erythroleukemic cells to activation-dependent monoclonal antibodies.

L. Parise, P. Patel, C. Boudignon-Proudhon, 1996, Blood.

Ulceration of primary melanoma and responsiveness to adjuvant interferon therapy: Analysis of the adjuvant trials EORTC18952 and EORTC18991 in 2,644 patients

A. Eggermont, A. Testori, P. Patel, 2009 .

Simultaneous estimation of metoprolol tartrate and chlorthalidone by using RP-HPLC and method development as per ICH guidelines

P. Patel, B. Kumar, D. Vijaysree, 2013 .

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.

R. Motzer, K. Pittman, C. Barrios, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)

T. Powles, F. Thistlethwaite, P. Patel, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stromal fibroblasts support dendritic cells to maintain IL-23/Th17 responses after exposure to ionizing radiation

P. Patel, A. Saalbach, A. Jackson, 2016, Journal of leukocyte biology.

Human Dendritic Cells Pathway Regulates IL-23 Expression by The Ataxia Telangiectasia Mutated Kinase

Madhusudan, C. Seedhouse, P. Patel, 2013 .

D. Schadendorf, R. Dummer, M. Gore, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exploring the Experiences of Cancer Patients With Chemotherapy-Induced Ototoxicity: Qualitative Study Using Online Health Care Forums

D. Hoare, D. Baguley, P. Patel, 2019, JMIR cancer.

Tumour‐mediated disruption of dendritic cell function: Inhibiting the MEK1/2‐p44/42 axis restores IL‐12 production and Th1‐generation

P. Patel, A. Jackson, Xingwu Zhu, 2008, International journal of cancer.